Kolexia
Niccoli Patricia Endocrinologie
Niccoli Patricia
Endocrinologie
Centre Paoli-Calmettes
Marseille, France
100 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs neuroendocrines Tumeurs du pancréas Carcinomes Paragangliome Tumeurs de la thyroïde Phéochromocytome Néoplasie endocrinienne multiple de type 1 Lymphomes Maladie de Hodgkin

Collaborateurs

Voir plus
Baudin Eric
Baudin Eric
Gustave-Roussy, Villejuif, France
Borson Chazot Francoise
Borson Chazot Francoise
Hôpital Louis Pradel, Bron, France
Lombard Bohas Catherine
Lombard Bohas Catherine
Hôpital Edouard Herriot, Lyon, France
Ruszniewski Philippe
Ruszniewski Philippe
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Ipsen
2 collaboration(s)
Dernière en 2023
Advanced Accelerator Applications
1 collaboration(s)
Dernière en 2022
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet (London, England)   22 février 2024
ASPEN: A Prospective Evaluation of the Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm
Essai Clinique (IRCCS San Raffaele)   17 janvier 2024
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas: A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Essai Clinique (Celgene)   07 décembre 2023
Genetic testing in prolactinomas: a cohort study.
European journal of endocrinology   13 novembre 2023
Outcome of nonfunctioning pancreatic neuroendocrine tumors after initial surveillance or surgical resection: a single-center observational study.
Annals of gastroenterology   30 octobre 2023
LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
NEONEC: Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   28 juin 2023
BEVANEC: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Essai Clinique (Hospices Civils de Lyon)   18 avril 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
The Lancet. Oncology   02 février 2023
Transarterial chemoembolization (TACE) for neuroendocrine liver metastasis (NELM): Predictive value of volumetric arterial enhancement (VAE) on baseline MRI.
Bulletin du cancer   31 janvier 2023